title: Temozolomide chemotherapy in patients with recurrent malignant gliomas.
abstract: Numerous studies have demonstrated the clinical activity of temozolomide, a second-generation alkylating agent, against malignant brain tumors, however, its activity has not been reported in an Asian population. This study analyzed the efficacy and toxicity of temozolomide in 25 adult patients with recurrent or progressive malignant gliomas after surgery and standard radiation therapy with or without chemotherapy, enrolled in our institution since July 2000. Sixteen patients had glioblastoma multiforme (GBM), six with anaplastic astrocytoma, and three with anaplastic oligodendroglioma. Of the 25 patients, 3 (12%) achieved a complete response (CR), 8 (32%) achieved a partial response (PR), 6 (24%) had stable disease (SD), and 8 (32%) had progressive disease (PD). Two patients achieved a CR, 4 patients achieved a PR, 3 patients had SD and 7 patients had PD in GBM, and 1 patient achieved a CR, 4 patients achieved a PR, 3 patients had SD, 1 patient had PD in the non-GBM patients. Median progression free survival was 8 weeks in GBM and 22 weeks in the non-GBM patients. The median overall survival of each group was 17 weeks and 28 weeks. Temozolomide demonstrated moderate activity in recurrent and progressive malignant gliomas without serious toxicity.
authors.affiliation: Department of Neurosurgery, The Catholic University of Korea, Seocho-gu, Seoul, Korea.
authors.forename: Seung-Ho
authors.initials: SH
authors.lastname: Yang
authors.forename: Moon-Kyu
authors.initials: MK
authors.lastname: Kim
authors.forename: Tae-Kyu
authors.initials: TK
authors.lastname: Lee
authors.forename: Kwan-Sung
authors.initials: KS
authors.lastname: Lee
authors.forename: Sin-Soo
authors.initials: SS
authors.lastname: Jeun
authors.forename: Chun-Kun
authors.initials: CK
authors.lastname: Park
authors.forename: Joon-Ki
authors.initials: JK
authors.lastname: Kang
authors.forename: Moon-Chan
authors.initials: MC
authors.lastname: Kim
authors.forename: Yong-Kil
authors.initials: YK
authors.lastname: Hong
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D056486:Chemical and Drug Induced Liver Injury; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009364:Neoplasm Recurrence, Local; D016019:Survival Analysis; D000077204:Temozolomide; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide